Phase 1 study of bortezomib in combination with melphalan and dexamethasone in Japanese patients with relapsed AL amyloidosis

Chihiro Shimazaki, Shin ichi Fuchida, Kenshi Suzuki, Tadao Ishida, Hirokazu Imai, Morio Sawamura, Hiroyuki Takamatsu, Masahiro Abe, Toshihiro Miyamoto, Hiroyuki Hata, Masahito Yamada, Yukio Ando

研究成果: ジャーナルへの寄稿記事

2 引用 (Scopus)

抜粋

Abstract: We performed a phase 1 study to evaluate the safety and feasibility of bortezomib (BOR) with melphalan and dexamethasone (BMD) in patients with light chain amyloidosis (AL) without severe cardiac failure. Patients received BOR on a twice-weekly schedule (days 1, 4, 8, and 11 of 28-day treatment cycles) at planned doses of 1.0 (dose level 1) and 1.3 (dose level 2) mg/m2 in combination with melphalan 8 mg/m2 on days 1–4 and dexamethasone 20 mg on days 1, 2, 4, 5, 8, 9, 11, and 12. Dose-limiting toxicity (DLT) was evaluated at the end of cycle one, and treatment was continued for four cycles. Six patients were enrolled at dose level 1, and one showed DLT (grade 3: herpes zoster). Further 3 patients were enrolled at dose level 2, and none experienced DLT. Thus, the maximum tolerated dose was defined as BOR doses of 1.3 mg/m2 for the twice-weekly schedule. A total of 32 cycles of BMD therapy were given, and the most common hematologic toxicity was thrombocytopenia (47 %). Peripheral neuropathy was the most common non-hematologic toxicity (16 %). We demonstrated that BMD is safe and tolerable for Japanese AL patients without severe cardiac damage. Clinical trial registration: UMIN000006604.

元の言語英語
ページ(範囲)79-85
ページ数7
ジャーナルInternational journal of hematology
103
発行部数1
DOI
出版物ステータス出版済み - 1 1 2016

    フィンガープリント

All Science Journal Classification (ASJC) codes

  • Hematology

これを引用